Pharma Equity Group ASOCSE:PEG Quick Ratio is 4.33 as of Dec. 2025, which is 0% below its 10-year median of 4.34. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Pharma Equity Group AS ranks better than 55.52% on this metric.
Pharma Equity Group AS has a quick ratio of 4.33. It generally indicates good short-term financial strength.
The historical rank and industry rank for Pharma Equity Group AS's Quick Ratio or its related term are showing as below:
OCSE:PEG'
s Quick Ratio Range Over the Past 10 Years
Min: 0.01 Med: 4.34 Max: 71.38
Current: 4.33
During the past 13 years, Pharma Equity Group AS's highest Quick Ratio was 71.38. The lowest was 0.01. And the median was 4.34.
OCSE:PEG's Quick Ratio is ranked better than 55.52% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs OCSE:PEG: 4.33
Pharma Equity Group AS (OCSE:PEG) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Pharma Equity Group AS Quick Ratio Related Terms
Pharma Equity Group AS Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:PEG vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Pharma Equity Group AS's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Equity Group AS (OCSE:PEG) has a Quick Ratio of 4.33 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Pharma Equity Group AS and its competitors. This is near median its historical median of 4.34. Over the past decade, Pharma Equity Group AS's Quick Ratio has ranged from 0.01 to 71.38. According to the industry distribution chart, Pharma Equity Group AS ranks #628 out of 1412 companies in the Biotechnology industry, placing it in the top 44.5%.
Is Pharma Equity Group AS's Quick Ratio too high?
Pharma Equity Group AS's current Quick Ratio of 4.33 is near median its 10-year median of 4.34. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 71.38. The Biotechnology industry median Quick Ratio is 3.60. Pharma Equity Group AS's value of 4.33 is 20.3% above this industry median. Based on the distribution chart, Pharma Equity Group AS ranks #628 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint.
How does Pharma Equity Group AS's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #628 out of 1412 companies for Quick Ratio. This puts Pharma Equity Group AS in the upper half of its industry. The industry median Quick Ratio is 3.60. Pharma Equity Group AS's value of 4.33 is 20.3% above this benchmark. Historically, Pharma Equity Group AS's own Quick Ratio has ranged from 0.01 to 71.38 over the past decade. While the company's 10-year median is 4.34 vs. the industry median of 3.60, Pharma Equity Group AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Equity Group AS's current Quick Ratio of 4.33 is 20.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Pharma Equity Group AS and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current Quick Ratio is 4.33, which is near median its own 10-year median of 4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Quick Ratio of 4.33. The current Quick Ratio is 4.33, which is near median its 10-year median of 4.34 and 20.3% above the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Quick Ratio is 4.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 